• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Akili Reports First Quarter 2023 Financial Results and Provides Business Update

    5/11/23 4:01:00 PM ET
    $AKLI
    Medical/Dental Instruments
    Health Care
    Get the next $AKLI alert in real time by email

    EndeavorRxⓇ prescriptions for children with ADHD increased 32% in Q1 2023 over Q4 2022

    Pivotal study in adults with ADHD showed significant improvements in attention and clinical outcomes, exceeding those observed in other age groups; Akili plans to include data in FDA regulatory submission later this year

    Akili, Inc. (NASDAQ:AKLI), a leading digital medicine company, today reported its financial results for the quarter ended March 31, 2023, and provided an update on business progress.

    "We're seeing steady, increasing uptake of EndeavorRx in the pediatric market," said Eddie Martucci, chief executive officer of Akili. "With the submission of our EndeavorRx adolescent label expansion data to the FDA and positive results from our pivotal trial in adults with ADHD, we now have the potential to greatly expand our current market and reach at least 14 million patients with ADHD in the U.S. With the ongoing mental health crisis and medication shortage affecting all ages, we intend to accelerate our plans to help these millions of patients in need."

    Business Update

    • A total of 2,372 prescriptions were written for EndeavorRx in the first quarter of 2023, representing a 32% increase over the fourth quarter of 2022 and 255% increase over the first quarter of 2022.
    • Prescriptions were written by 920 unique prescribers in the first quarter of 2023, a 15% increase over the fourth quarter of 2022 and 111% growth over the first quarter of 2022, driven by increases in both new and repeat prescribers.
    • The number of prescription refills written for EndeavorRx increased 23% in the first quarter of 2023 over the fourth quarter of 2022 and grew by 447% over the first quarter of 2022.
    • On May 3, 2023, Akili announced topline results from STARS-ADHD-Adult, its pivotal trial of EndeavorRx (AKL-T01) in adults with ADHD. The study showed significant improvements in attention function, nearly seven times as large as the changes seen in the STARS-ADHD study data used in the Company's successful filing for its current FDA authorization in children ages 8-12. Significant improvements were also seen across clinical outcomes, including quality of life. An estimated eleven million adults in the United States are living with ADHD, and the Company plans to use the STARS-ADHD-Adult study data to support the launch of an adult product as soon as possible.
    • On May 8, 2023, Akili submitted data from STARS-ADHD-Adolescents, the Company's pivotal trial of AKL-T01 in 13 to 17 year olds with ADHD, to FDA to expand its current EndeavorRx label to include adolescents. If the label expansion is approved by FDA, it would approximately double the size of the Company's ADHD market opportunity. Full study results from the adolescent study will be presented at the 2023 American Society of Clinical Psychopharmacology Annual Meeting on May 31.

    First Quarter 2023 Financial Highlights

    • Cash position: Cash, cash equivalents, and short-term investments as of March 31, 2023 were $117.4 million. The Company's cash, cash equivalents, and short-term investments as of March 31, 2023 are expected to be sufficient to fund current and planned operations into the first quarter of 2025.
    • Revenues: Total revenues for the first quarter of 2023 were $113 thousand compared to $111 thousand for the fourth quarter of 2022. The difference between revenue growth and overall prescription growth was driven by an increase in the deferred revenue balance at the end of the first quarter of 2023 mainly due to the timing of prescriptions dispensed in the quarter.
    • Total Operating Expenses: GAAP total operating expenses were $19.1 million for the first quarter of 2023, compared to $22.1 million for the fourth quarter of 2022. Non-GAAP total operating expenses were $14.0 million for the first quarter of 2023, compared to $20.0 million for the fourth quarter of 2022. The decrease in expenses was driven primarily by a decrease in personnel costs across the organization, lower clinical trials costs, and reduction in marketing-related spend for EndeavorRx, partially offset by growth in the sales organization.
    • Net income (loss): GAAP net loss was $20.7 million for the first quarter of 2023, compared to a net loss of $16.8 million for the fourth quarter of 2022, driven primarily by the fluctuation in the liability associated with the Company's earnout shares during each quarter. Non-GAAP net loss was $13.6 million for the first quarter of 2023, compared to a net loss of $19.5 million for the fourth quarter of 2022, driven primarily by lower operating expenses in the first quarter of 2023.

    For additional information, please see the tables below, which include a reconciliation of the historical non-GAAP financial measures to GAAP financial measures.

    Webcast and Conference Call

    Akili will host a conference call and webcast today, Thursday, May 11, 2023, at 4:30 p.m. ET. A live audio webcast of the conference call and presentation will be available at www.akiliinteractive.com under Investor Relations, Events & Presentations, along with slides that may be referenced during the call. An archived version of the webcast will be available on the Company's website following the event.

    To access the call, dial 888-575-5163 (toll-free) or 416-764-8620 (international) and reference "Akili Q1 2023 Earnings."

    Non-GAAP Financial Measures

    In addition to financial information prepared and presented in accordance with generally accepted accounting principles in the United States (GAAP), this press release includes the following non-GAAP financial measures: non-GAAP total operating expenses on a historical basis and non-GAAP net loss on a historical basis. Akili derives these non-GAAP financial measures by excluding certain expenses and other items from the respective GAAP financial measure that is most directly comparable to each non-GAAP financial measure. Specifically, the non-GAAP total operating expenses exclude stock-based compensation expense and severance and termination related costs associated with the workforce reduction announced in January 2023, and non-GAAP net loss excludes stock-based compensation expense, severance and termination related costs associated with the workforce reduction announced in January 2023, and the change in estimated fair value of earn-out liabilities. Akili's management believes that these non-GAAP financial measures are useful to both management and investors in analyzing its ongoing business and operating performance. Management does not intend the presentation of these non-GAAP financial measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP, but as a complement to provide greater transparency. In addition, these non-GAAP financial measures may differ from similarly named measures used by other companies. A reconciliation of the historical non-GAAP financial measures to GAAP financial measures is included in the attached financial tables.

    EndeavorRx Indication and Overview

    EndeavorRx is the first-and-only FDA-authorized treatment delivered through a video game experience. EndeavorRx is indicated to improve attention function as measured by computer-based testing in children ages 8 to 12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure Test of Variables of Attention (TOVA®) of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder. EndeavorRx is available by prescription only. It is not intended to be used as a stand-alone therapeutic and is not a substitution for a child's medication. The most common side effect observed in children in EndeavorRx's clinical trials was a feeling of frustration, as the game can be quite challenging at times. No serious adverse events were associated with its use. EndeavorRx is recommended to be used for approximately 25 minutes a day, 5 days a week, over initially at least 4 consecutive weeks, or as recommended by your child's health care provider. To learn more about EndeavorRx, please visit EndeavorRx.com.

    About Akili

    Akili is pioneering the development of cognitive treatments through game-changing technologies. Akili's approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device but experienced like entertainment. Akili's platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili's belief that effective medicine can also be fun and engaging, Akili's products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements include, without limitation, statements in this press release related to: our expectations regarding the potential expansion of our current pediatric market; our expectations regarding our potential to reach at least 14 million patients with ADHD in the U.S., our intent to accelerate our plans to commercialize products for the adolescent and adult populations; our plans to use the STARS-ADHD-Adult study data in a regulatory submission later this year; our plans to use the STARS-ADHD-Adult study data to support the launch of an adult product as soon as possible; our expectation that our regulatory submission to FDA to seek a potential label expansion for EndeavorRx in ADHD to include adolescents will significantly increase the size of our ADHD market opportunity; and our expectation that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our current and planned operations into the first quarter of 2025. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to: our ability to successfully further commercialize EndeavorRx; our ability to successfully create, and navigate, a new category of medicine and to achieve broad adoption of digital therapeutics among healthcare providers, caregivers, and patients; our ability to obtain and maintain adequate coverage and reimbursement for our digital therapeutics; our ability to continue to advance our clinical development pipeline; our ability to defend our intellectual property and satisfy various FDA and other regulatory requirements in and outside of the United States; the impact of the COVID-19 pandemic on our business; the risk of downturns and a changing regulatory landscape in the highly competitive industry in which we operate; the timing and results expected from our and our partners' clinical trials and our reliance on third parties for certain aspects of our business; our ability to accurately estimate expenses, capital requirements, and needs for additional financing; and other risks identified in our current filings and any subsequent filings made with the Securities and Exchange Commission (SEC). We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof and should not be relied upon as representing our views as of any subsequent date. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

    Akili, Inc.
    Unaudited Condensed Consolidated Balance Sheets
     

    March 31,

    December 31,

    March 31,

    2023

    2022

    2022

     
    Assets
    Current assets:
    Cash and cash equivalents

    $

    87,869

     

    $

    54,097

     

    $

    39,754

     

    Restricted cash

     

    305

     

     

    305

     

     

    305

     

    Short-term investments

     

    29,571

     

     

    82,034

     

     

    14,973

     

    Accounts receivable

     

    49

     

     

    41

     

     

    33

     

    Prepaid expenses and other current assets

     

    3,531

     

     

    4,565

     

     

    4,254

     

    Total current assets

     

    121,325

     

     

    141,042

     

     

    59,319

     

    Property and equipment, net

     

    844

     

     

    919

     

     

    1,118

     

    Operating lease right-of-use asset

     

    2,427

     

     

    2,596

     

     

    2,807

     

    Prepaid expenses and other long-term assets

     

    1

     

     

    -

     

     

    5

     

    Total assets

    $

    124,597

     

    $

    144,557

     

    $

    63,249

     

    Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)
    Current liabilities:
    Accounts payable

    $

    1,413

     

    $

    2,681

     

    $

    3,234

     

    Accrued expenses and other current liabilities

     

    2,828

     

     

    5,616

     

     

    3,769

     

    Deferred revenue

     

    120

     

     

    106

     

     

    123

     

    Deferred rent, short term

     

    -

     

     

    -

     

     

    16

     

    Operating lease liability

     

    809

     

     

    826

     

     

    605

     

    Note payable, short term

     

    6,250

     

     

    4,375

     

     

    -

     

    Total current liabilities

     

    11,420

     

     

    13,604

     

     

    7,747

     

    Note payable, long term

     

    8,706

     

     

    10,442

     

     

    4,823

     

    Operating lease liability, net of current portion

     

    2,307

     

     

    2,485

     

     

    2,995

     

    Corporate bond, net of bond discount

     

    1,888

     

     

    1,834

     

     

    1,686

     

    Earn-out liabilities

     

    7,836

     

     

    5,513

     

     

    -

     

    Total liabilities

     

    32,157

     

     

    33,878

     

     

    17,251

     

    Commitments and contingencies
    Redeemable convertible preferred stock

     

    -

     

     

    -

     

     

    296,191

     

    Stockholders' equity (deficit)
    Common stock

     

    8

     

     

    8

     

     

    -

     

    Additional paid-in capital

     

    353,429

     

     

    350,980

     

     

    -

     

    Accumulated deficit

     

    (260,999

    )

     

    (240,288

    )

     

    (250,187

    )

    Accumulated other comprehensive income (loss)

     

    2

     

     

    (21

    )

     

    (6

    )

    Total stockholders' equity (deficit)

     

    92,440

     

     

    110,679

     

     

    (250,193

    )

    Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)

    $

    124,597

     

    $

    144,557

     

    $

    63,249

     

     
    Akili, Inc.
    Unaudited Condensed Consolidated Statements of Operations
     

    Three Months Ended

    March 31,

    Three Months Ended

    December 31,

    2023

    2022

    2022

    Revenues

    $

    113

     

    $

    66

     

    $

    111

     

    Cost of revenues

     

    137

     

     

    96

     

     

    125

     

    Gross loss

     

    (24

    )

     

    (30

    )

     

    (14

    )

    Operating expenses:
    Research and development

     

    6,084

     

     

    6,304

     

     

    7,642

     

    Selling, general and administrative

     

    13,011

     

     

    15,391

     

     

    14,451

     

    Total operating expenses

     

    19,095

     

     

    21,695

     

     

    22,093

     

    Operating loss

     

    (19,119

    )

     

    (21,725

    )

     

    (22,107

    )

    Other income (expense), net

     

    (1,592

    )

     

    (167

    )

     

    5,311

     

    Income tax expense

     

    -

     

     

    -

     

     

    (19

    )

    Net loss

    $

    (20,711

    )

    $

    (21,892

    )

    $

    (16,815

    )

     
    Akili, Inc.
    GAAP to Non-GAAP Reconciliation
     

    Three Months Ended

    March 31,

    Three Months Ended

    December 31,

    2023

    2022

    2022

     
    GAAP Total Operating Expenses

    $

    19,095

     

    $

    21,695

     

    $

    22,093

     

    Stock-based compensation

     

    (2,759

    )

     

    (2,070

    )

     

    (2,117

    )

    Expenses related to workforce reduction

     

    (2,329

    )

     

    -

     

     

    -

     

    Non-GAAP Total Operating Expenses

    $

    14,007

     

    $

    19,625

     

    $

    19,976

     

     
    GAAP Net Loss

    $

    (20,711

    )

    $

    (21,892

    )

    $

    (16,815

    )

    Stock-based compensation

     

    2,759

     

     

    2,070

     

     

    2,117

     

    Expenses related to workforce reduction

     

    2,329

     

     

    -

     

     

    -

     

    Change in estimated fair value for earnout liabilities

     

    2,013

     

     

    -

     

     

    (4,842

    )

    Non-GAAP Net Loss

    $

    (13,610

    )

    $

    (19,822

    )

    $

    (19,540

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005170/en/

    Get the next $AKLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AKLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Akili Inc.

      SC 13D/A - Akili, Inc. (0001850266) (Subject)

      7/9/24 8:05:26 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Akili Inc.

      SC 13D/A - Akili, Inc. (0001850266) (Subject)

      7/5/24 5:36:11 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Akili Inc.

      SC 13G/A - Akili, Inc. (0001850266) (Subject)

      7/5/24 12:05:26 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care

    $AKLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PureTech Health plc – Half-Year Report

      Strong progress across PureTech's portfolio, with significant near-term catalysts Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and $50 million buyback completed Strong balance sheet with expected operational runway for at least three years Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will be filed on Form 6-K w

      8/28/24 2:01:00 AM ET
      $AKLI
      $BMY
      $PRTC
      $VOR
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Virtual Therapeutics Announces Results of Tender Offer to Acquire Akili Interactive

      Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games ("Virtual Therapeutics"), today announced that it has successfully completed the tender offer commenced on June 3, 2024, to acquire all outstanding shares of common stock of Akili, Inc. (NASDAQ:AKLI) ("Akili") for $0.4340 per share (the "Offer Price"). The tender offer expired at one minute after 11:59 p.m. EDT on July 1, 2024 (the "Expiration Date"). As of the Expiration Date, a total of 69,674,538 shares, representing approximately 88.2% of the outstanding shares of common stock of Akili, were validly tendered and not validly withdrawn. The number of shares validly tendered in acc

      7/2/24 7:19:00 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game

      Clinically proven to improve attention function, EndeavorOTCⓇ is the first and only digital therapeutic cleared by FDA as an over-the-counter treatment for adults with ADHD Akili, Inc. (NASDAQ:AKLI), a leading digital therapeutics company, today announced U.S. Food and Drug Administration (FDA) clearance of EndeavorOTCⓇ (AKL-T01) as an over-the-counter treatment for adults with attention-deficit/hyperactivity disorder (ADHD). Delivered through an engaging video game experience, EndeavorOTC is indicated to improve attention function as measured by computer-based testing in men and women with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. EndeavorOTC i

      6/18/24 4:01:00 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care

    $AKLI
    SEC Filings

    See more

    $AKLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AKLI
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form 15-12G filed by Akili Inc.

      15-12G - Akili, Inc. (0001850266) (Filer)

      7/12/24 5:16:02 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Akili Inc.

      EFFECT - Akili, Inc. (0001850266) (Filer)

      7/10/24 12:15:03 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Akili Inc.

      S-8 POS - Akili, Inc. (0001850266) (Filer)

      7/2/24 10:00:03 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Large owner Puretech Health Plc

      4 - Akili, Inc. (0001850266) (Issuer)

      7/8/24 7:42:32 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Large owner Palihapitiya Chamath

      4 - Akili, Inc. (0001850266) (Issuer)

      7/5/24 5:36:39 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Large owner Temasek Holdings (Private) Ltd

      4 - Akili, Inc. (0001850266) (Issuer)

      7/5/24 11:54:03 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • Akili Announces Leadership Transition

      Co-founder and CEO Eddie Martucci, Ph.D. transitions to role of Board chair; Matt Franklin, president and chief operating officer of Akili, appointed president and chief executive officer Akili, Inc. (NASDAQ:AKLI), a leading digital medicine company, today announced that Eddie Martucci transitioned to the role of Board chair, and Matt Franklin has been appointed to serve as president and CEO of the company and as a member of its board of directors, effective October 5, 2023. Martucci replaces former Board chair, Chamath Palihapitiya, who has resigned from the Board, effective October 4, 2023. The leadership transition follows the company's announcement in September that it plans to shif

      10/6/23 7:00:00 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care

    $AKLI
    Financials

    Live finance-specific insights

    See more
    • PureTech Health plc – Half-Year Report

      Strong progress across PureTech's portfolio, with significant near-term catalysts Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and $50 million buyback completed Strong balance sheet with expected operational runway for at least three years Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will be filed on Form 6-K w

      8/28/24 2:01:00 AM ET
      $AKLI
      $BMY
      $PRTC
      $VOR
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results

      Shionogi amendment provides Akili with near-term cash payments and cancellation of debt obligation Company announces exploration of strategic alternatives and associated workforce reduction Company to release first quarter 2024 financial results on May 14, 2024 Akili, Inc. (NASDAQ:AKLI), a leading digital medicine company, today provided several corporate updates, including an amendment to its strategic distribution agreement with Shionogi & Co., Ltd. ("Shionogi"), a leading global pharmaceutical company. Under the terms of the amended agreement, Shionogi has canceled and forgiven a $5.0 million long-term debt obligation and agreed to make certain payments for SDT-001 (the Japanese, l

      4/30/24 8:00:00 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates

      Plans to disclose Q4/FY 2023 financial results on February 29, 2024; CEO Matthew Franklin to participate in fireside chat at TD Cowen's 44th Annual Healthcare Conference on March 4, 2024 Appointed John Spinale to Board of Directors and Audit Committee; provides update regarding plans for April 17, 2024 Annual Meeting and efforts to regain compliance with Nasdaq rules Akili, Inc. (NASDAQ:AKLI), a leading digital medicine company, today provided several corporate updates, including that it plans to report fourth quarter and full year 2023 financial results and a business update via press release on Thursday, February 29, 2024 after the market closes. The company will not be hosting an ear

      2/21/24 4:05:00 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care